Product Information
CHLORDIAZEPO-AMITRIPTYL 5-12.5 is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.2040 per EA under NDC 00378021101. Its NADAC has been published 463 times since Nov 28, 2013.
FDA first approved this application on Dec 10, 1986.
Strength
14; 5 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378021101
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDEApproval Type
Generic (ANDA)
FDA Application
ANDA071297FDA Approved
12/10/1986
On Market Since
12/10/1986
Pharmacological Classes
Price Statistics
The NADAC for CHLORDIAZEPO-AMITRIPTYL 5-12.5 has been published 463 times since Nov 28, 2013, and over the history we have for it it has risen 46.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2040 per EA |
|---|---|
| All-time high | $1.2691 (Apr 12, 2017) |
| All-time low | $0.8211 (Nov 28, 2013) |
| 52-week high | $1.2040 |
| 52-week low | $1.1808 |
| Median price | $1.1702 |
| Average price | $1.1532 |
| Largest weekly change | +19.0% (Jul 23, 2014) |
| Weeks tracked | 463 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
chlordiazepoxide and amitriptyline hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CHLORDIAZEPO-AMITRIPTYL 5-12.5?
The current National Average Drug Acquisition Cost (NADAC) for CHLORDIAZEPO-AMITRIPTYL 5-12.5, manufactured by Mylan Pharmaceuticals Inc., is $1.2040 per EA (NDC 00378021101), effective Sep 30, 2026.
How has the price of CHLORDIAZEPO-AMITRIPTYL 5-12.5 changed over time?
Over the history we have for it, the NADAC for CHLORDIAZEPO-AMITRIPTYL 5-12.5 has risen 46.6%. It has been tracked across 463 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CHLORDIAZEPO-AMITRIPTYL 5-12.5?
Since Nov 28, 2013, the NADAC for CHLORDIAZEPO-AMITRIPTYL 5-12.5 has ranged from a low of $0.8211 (Nov 28, 2013) to a high of $1.2691 (Apr 12, 2017), with a median of $1.1702 per EA.
Are there cheaper alternatives to CHLORDIAZEPO-AMITRIPTYL 5-12.5?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CHLORDIAZEPO-AMITRIPTYL 5-12.5 in a comparable dosage form, but none are currently priced below it.
Who manufactures CHLORDIAZEPO-AMITRIPTYL 5-12.5?
CHLORDIAZEPO-AMITRIPTYL 5-12.5 (NDC 00378021101) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.